Literature DB >> 2166091

Measurement of rotavirus-neutralizing coproantibody in children by fluorescent focus reduction assay.

B S Coulson1, P J Masendycz.   

Abstract

A fluorescent focus reduction assay suitable for the measurement of rotavirus-neutralizing antibodies in the feces of children was developed. Of 408 stools tested, 7% showed false-positive neutralization, and the number of rotavirus serotypes neutralized by a fecal extract was proportional to the levels of antirotaviral immunoglobulin A in the extract.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2166091      PMCID： PMC268008          DOI： 10.1128/jcm.28.7.1652-1654.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  9 in total

1.  Evaluation of end-point titration, single dilution and capture enzyme immunoassays for measurement of antirotaviral IgA and IgM in infantile secretions and serum.

Authors:  B S Coulson; K Grimwood; R F Bishop; G L Barnes
Journal:  J Virol Methods       Date:  1989-10       Impact factor: 2.014

2.  Neutralizing monoclonal antibodies to human rotavirus and indications of antigenic drift among strains from neonates.

Authors:  B S Coulson; K J Fowler; R F Bishop; R G Cotton
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

3.  The enzyme-linked immunosorbent assay (ELISA): a measure of antibody concentration or affinity.

Authors:  J E Butler; T L Feldbush; P L McGivern; N Stewart
Journal:  Immunochemistry       Date:  1978-02

4.  Changes in antibody avidity after virus infections: detection by an immunosorbent assay in which a mild protein-denaturing agent is employed.

Authors:  S Inouye; A Hasegawa; S Matsuno; S Katow
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

5.  Production and preliminary characterization of monoclonal antibodies directed at two surface proteins of rhesus rotavirus.

Authors:  H B Greenberg; J Valdesuso; K van Wyke; K Midthun; M Walsh; V McAuliffe; R G Wyatt; A R Kalica; J Flores; Y Hoshino
Journal:  J Virol       Date:  1983-08       Impact factor: 5.103

6.  Sialic acid glycoproteins inhibit in vitro and in vivo replication of rotaviruses.

Authors:  R H Yolken; R Willoughby; S B Wee; R Miskuff; S Vonderfecht
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

7.  Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus.

Authors:  R L Ward; D I Bernstein; R Shukla; E C Young; J R Sherwood; M M McNeal; M C Walker; G M Schiff
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

8.  Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance.

Authors:  A Z Kapikian; R G Wyatt; M M Levine; R H Yolken; D H VanKirk; R Dolin; H B Greenberg; R M Chanock
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

9.  Comparison of serum and mucosal antibody responses following severe acute rotavirus gastroenteritis in young children.

Authors:  K Grimwood; J C Lund; B S Coulson; I L Hudson; R F Bishop; G L Barnes
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948
  9 in total
  5 in total

1.  Expression of human rotavirus chimeric fusion proteins from replicating but non disseminating adenovectors and elicitation of rotavirus-specific immune responses in mice.

Authors:  Aurélie Girard; Elodie Roques; Marie-Claude St-Louis; Bernard Massie; Denis Archambault
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

2.  Longitudinal studies of neutralizing antibody responses to rotavirus in stools and sera of children following severe rotavirus gastroenteritis.

Authors:  B S Coulson
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

3.  Role of coproantibody in clinical protection of children during reinfection with rotavirus.

Authors:  B S Coulson; K Grimwood; I L Hudson; G L Barnes; R F Bishop
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

4.  Flagellin in fusion with human rotavirus structural proteins exerts an adjuvant effect when delivered with replicating but non-disseminating adenovectors through the intrarectal route.

Authors:  Aurélie Girard; Elodie Roques; Bernard Massie; Denis Archambault
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

5.  Gene-edited vero cells as rotavirus vaccine substrates.

Authors:  Nichole Orr-Burks; Jackelyn Murray; Weilin Wu; Carl D Kirkwood; Kyle V Todd; Les Jones; Abhijeet Bakre; Houping Wang; Baoming Jiang; Ralph A Tripp
Journal:  Vaccine X       Date:  2019-10-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.